The latest report by IMARC Group, titled "Legionella Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027," finds that the global Legionella testing market size reached US$ 261 Million in 2021. Legionella is a genus of waterborne bacteria that can cause severe pneumonia, also known as Legionnaires' disease, Pontiac fever, and illness with flu-like symptoms. Its testing helps to identify the presence of bacteria or antigens in the blood, urine, and sputum. Presently, various testing methods are performed to diagnose Legionella disease, including urinary antigen, paired serology, Direct Fluorescent Antibody (DFA) stain, Polymerase Chain Reaction (PCR), and culture of lower respiratory secretions.
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Global Legionella Testing Market Trends:
The market is primarily driven by the rising geriatric population across the globe, as adults over the age of 50 years are prone to developing Legionella. In addition, the growing prevalence of chronic disorders such as cancer, diabetes, kidney disease, and human immunodeficiency virus (HIV) represents another major growth-inducing factor. Since patients with chronic illness are at a higher risk of developing Legionella infection, there is an increase in the demand for its effective diagnostic tests and treatments. Moreover, as Legionella-causing bacteria are majorly found in different natural and artificial aquatic environments, health agencies of numerous countries are developing an effective water safety plan (WSP) to minimize the proliferation of bacteria in the water, which is escalating the demand for Legionella testing in workplace buildings. Furthermore, the increasing clinical trials on diagnostic and treatment strategies for adult patients with community-acquired pneumonia are anticipated to propel the market growth in the coming years. Looking forward, IMARC Group expects the market value to reach US$ 424 Million by 2027, exhibiting a CAGR of 8.38% during the forecast period (2022-2027).
- Based on the application, the market has been bifurcated into water testing (microbial culture, DFA stain, PCR, and others) and IVD testing (blood culture, urine antigen test, DFA stain, PCR, and others).
- On the basis of the end user, the market has been segmented into diagnostic laboratories, hospitals and clinics, and others.
- Region-wise, the market has been divided into Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), North America (the United States and Canada), Asia Pacific (China, Japan, Australia, South Korea, Indonesia, Singapore and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
- The competitive landscape of the industry has also been examined, with some of the key players being Abbott Laboratories, Becton, Dickinson and Company, BioMérieux SA, Bio-Rad Laboratories Inc, Eiken Chemical Co. Ltd, Quidel Corporation, Takara Bio Inc., and Thermo Fisher Scientific Inc.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Follow us on twitter : @imarcglobal